Prof. Naftali Tishby dreams of the day when we will be able transfer a copy of our souls onto the computer before our death so that the soul will continue to think, feel, and answer our grandchildren's questions long after our bodies disintegrate. Prof. Tishby of the Interdisciplinary Center for Neural Computation (ICNC) at the Hebrew University of Jerusalem believes that this day is near.
The French-Israeli eye drug maker uses technology developed by the Hebrew University of Jerusalem.
Merck shopping for new technologies for the improvement of drug development
Jerusalem Development Authority allocates initial 10 million NIS to BioJerusalem
Reinventing the wheel- the latest car technology on the Wall Street Journal
A Hebrew University doctoral student who is the first cousin of the president of Chile has won a prestigious research prize for developing a "knockout technique" in special "antibody nose drops" against allergies that he tested successfully on lab mice.
Nava Swersky Sofer isn't the type of person to look back at her accomplishments and congratulate herself. Instead, she says, she's a forward thinker who focuses keenly on her next move.
Tiltan attacks cancer using four different materials
The company has developed a method for applying transgenic tobacco to produce human recombinant collagen.
CBI will purchase 24% of the cancer-drug developer; Yissum keeps its royalties agreement
Novagali Pharma Announces Positive Vekacia(R) Clinical Results from Pivotal Phase III Trial in Vernal Keratoconjunctivitis
Four years after the first information on featherless broiler research was known, the attention of the public and world media was attracted. Commercial trials show the big advantage over their feathered relatives, especially when kept in tropical regions.
Bioline will develop a new drug based on the technology of Prof. Hillel Bercovier and Dr. Ayelet Barenholz of the Hebrew university.
The agreement is reportedly worth several million dollars.
Yissum subsidiary Target-In and Indian company Century Pharmaceuticals will jointly develop a new drug for asthma and allergy, which will be based on the molecule developed by the Israel company.
(Hebrew article attached)
A facility for cross-disciplinary scientific research on a more comprehensive scale than has been
attempted anywhere is being launched by the Hebrew University of Jerusalem, in cooperation
with Yissum, the technology transfer company of the university.
These yellow cherry tomato seeds, named Summer Sun, were developed by Hazera
Genetics, part of the French-based global group Vilmorin Clause & Cie, in
collaboration with the Faculty of Agriculture at the Hebrew University.
This grant was received from the World Fund for Juvenile Diabetes Research and D-Cure. (Hebrew article attached)
Yissum will aid Kazakhstan in establishing technology transfer facilities as part of the Kazakhstan National Center for Biotechnology. (Hebrew article attached)
Biocancell Therapeutics Ltd.’s IPO benefited from both investor confidence in the company and lucky timing. Scheduled during the war, it was held on the day the cease-fire went into effect, when trading on the Tel Aviv Stock Exchange (TASE) was mixed.